TY - JOUR
T1 - Baseline cardiovascular risk in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial
AU - Soliman, Ez
AU - Sharma, S.
AU - Arastéh, K.
AU - Wohl, D.
AU - Achhra, A.
AU - Tambussi, G.
AU - O'Connor, J.
AU - Stein, Jh
AU - Duprez, Da
AU - Neaton, Jd
AU - Phillips, A.
PY - 2015/4/1
Y1 - 2015/4/1
N2 - Objectives: The Strategic Timing of AntiRetroviral Treatment (START) trial has recruited antiretroviral-naïve individuals with high CD4 cell counts from all regions of the world. We describe the distribution of cardiovascular disease (CVD) risk factors, overall and by geographical region, at study baseline. Methods: The distribution of CVD risk factors was assessed and compared by geographical region among START participants who had a baseline electrocardiogram (n=4019; North America, 11%; Europe/Australia/Israel, 36%; South America, 26%; Asia, 4%; Africa, 23%; median age 36 years; 26% female). Results: About 58.3% (n=2344) of the participants had at least one CVD risk factor and 18.9% (n=761) had two or more. The most common CVD risk factors were current smoking (32%), hypertension (19.3%) and obesity (16.5%). There were significant differences in the prevalence of CVD risk factors among geographical regions. The prevalence of at least one risk factor across regions was as follows: North America, 70.0%; Europe/Australia/Israel, 65.1%; South America, 49.4%; Asia, 37.0%; Africa, 55.8% (P-value
AB - Objectives: The Strategic Timing of AntiRetroviral Treatment (START) trial has recruited antiretroviral-naïve individuals with high CD4 cell counts from all regions of the world. We describe the distribution of cardiovascular disease (CVD) risk factors, overall and by geographical region, at study baseline. Methods: The distribution of CVD risk factors was assessed and compared by geographical region among START participants who had a baseline electrocardiogram (n=4019; North America, 11%; Europe/Australia/Israel, 36%; South America, 26%; Asia, 4%; Africa, 23%; median age 36 years; 26% female). Results: About 58.3% (n=2344) of the participants had at least one CVD risk factor and 18.9% (n=761) had two or more. The most common CVD risk factors were current smoking (32%), hypertension (19.3%) and obesity (16.5%). There were significant differences in the prevalence of CVD risk factors among geographical regions. The prevalence of at least one risk factor across regions was as follows: North America, 70.0%; Europe/Australia/Israel, 65.1%; South America, 49.4%; Asia, 37.0%; Africa, 55.8% (P-value
KW - Cardiovascular risk
KW - HIV
KW - Strategic Timing of AntiRetroviral Treatment (START) trial
UR - http://www.scopus.com/inward/record.url?scp=84923345073&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84923345073&partnerID=8YFLogxK
U2 - 10.1111/hiv.12233
DO - 10.1111/hiv.12233
M3 - Article
C2 - 25711323
AN - SCOPUS:84923345073
VL - 16
SP - 46
EP - 54
JO - HIV Medicine
JF - HIV Medicine
SN - 1464-2662
IS - S1
ER -